CHM 2301 / Chimeric Therap, Case Western Reserve University - LARVOL DELTA

CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers. (PubMed, Acta Pharm Sin B) - "The combination of CDH17-CAR-NK cells with CV1 emerges as a potential combinatorial approach to overcome the limitations of CAR-NK therapy. Further investigations are warranted to speed up the clinical translation of these findings."

Journal • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17 • SIRPA

Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer. (ASCO 2023) - " Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials."

IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immune Modulation • Oncology • Solid Tumor • CDH17 • LAMP1 • TNFA